Who owns BRIDGEBIO ONCOLOGY THERAPEUT?
- Ticker: BBOT
- CUSIP Number: 107924102
Tip: Access positions for across all investors
Analyze quarterly positions in Bridgebio Oncology Therapeut with up to 7 years of data, all consolidated into one spreadsheet
Download as csv
Download as Excel
Top investors of Bridgebio Oncology Therapeut stock
Who bought or sold BRIDGEBIO ONCOLOGY THERAPEUT this quarter?
| Fund or Company Name | Shares Held | Valued At | Change in Shares | As Of | Actions |
|---|---|---|---|---|---|
| Cormorant Asset Management | 18M | $160M | 0% | Mar 2026 |
|
| Deerfield Management Company | 4.9M | $44M | 0% | Mar 2026 |
|
| Omega Fund Management | 3.3M | $41M | 0% | Dec 2025 |
|
| EcoR1 Capital | 2.8M | $25M | 0% | Mar 2026 |
|
| Alphabet | 2.8M | $25M | 0% | Mar 2026 |
|
| Wellington Management Company | 2.8M | $25M | -3% | Mar 2026 |
|
| Enavate Sciences GP | 2.6M | $24M | 0% | Mar 2026 |
|
| Citadel Advisors | 2.5M | $23M | 0% | Mar 2026 |
|
| Novo A/S | 2.2M | $20M | 11% | Mar 2026 |
|
| BlackRock | 2.1M | $19M | 0% | Mar 2026 |
|
| Laurion Capital Management | 1.9M | $17M | 31% | Mar 2026 |
|
| Armistice Capital | 1.3M | $12M | 222% | Mar 2026 |
|
| Eventide Asset Management | 1.1M | $13M | 0% | Dec 2025 |
|
| Aisling Capital Management | 1.0M | $9.1M | 80% | Mar 2026 |
|
| Paradigm Biocapital Advisors | 868k | $7.8M | -62% | Mar 2026 |
|
| Vanguard Group | 791k | $9.9M | 22% | Dec 2025 |
|
| Octagon Capital Advisors | 719k | $6.4M | -31% | Mar 2026 |
|
| Royce & Associates | 637k | $5.7M | 100% | Mar 2026 |
|
| Geode Capital Management | 579k | $5.2M | 3% | Mar 2026 |
|
| Vanguard Capital Management | 538k | $4.8M | 100% | Mar 2026 |
|
| Adage Capital Partners GP | 400k | $3.6M | -71% | Mar 2026 |
|
| Ensign Peak Advisors | 321k | $2.9M | 100% | Mar 2026 |
|
| Charles Schwab Investment Management | 291k | $2.6M | 4% | Mar 2026 |
|
| Casdin Capital | 282k | $2.5M | 0% | Mar 2026 |
|
| Ikarian Capital | 270k | $2.4M | 23% | Mar 2026 |
|
| Millennium Management | 266k | $2.4M | 10% | Mar 2026 |
|
| Vanguard Fiduciary Trust | 254k | $2.3M | 100% | Mar 2026 |
|
| Schroder Investment Management Group | 249k | $2.2M | 100% | Mar 2026 |
|
| FMR | 240k | $2.2M | 0% | Mar 2026 |
|
| Granahan Investment Management | 231k | $2.1M | 100% | Mar 2026 |
|
| State Street Corporation | 226k | $2.0M | 4% | Mar 2026 |
|
| Goldman Sachs Group | 168k | $1.5M | 77% | Mar 2026 |
|
| Sio Capital Management | 131k | $1.2M | 0% | Mar 2026 |
|
| Hudson Bay Capital Management | 110k | $985k | 100% | Mar 2026 |
|
| Woodline Partners | 104k | $928k | 0% | Mar 2026 |
|
| Renaissance Technologies | 102k | $912k | 37% | Mar 2026 |
|
| Moore Capital Management | 100k | $895k | 0% | Mar 2026 |
|
| Bnp Paribas Arbitrage, Snc | 91k | $813k | 243% | Mar 2026 |
|
| Toroso Investments | 82k | $735k | 100% | Mar 2026 |
|
| Tema Etfs | 82k | $735k | 100% | Mar 2026 |
|
| Boothbay Fund Management | 81k | $724k | 21% | Mar 2026 |
|
| HighVista Strategies | 78k | $700k | -66% | Mar 2026 |
|
| Northern Trust | 58k | $727k | -40% | Dec 2025 |
|
| TD Asset Management | 58k | $515k | -51% | Mar 2026 |
|
| Opaleye Management | 53k | $477k | 100% | Mar 2026 |
|
| UBS Group | 51k | $452k | -46% | Mar 2026 |
|
| Avidity Partners Management | 44k | $393k | 100% | Mar 2026 |
|
| Morgan Stanley | 43k | $388k | 202% | Mar 2026 |
|
| Squarepoint Ops | 43k | $387k | 275% | Mar 2026 |
|
| Qube Research & Technologies | 36k | $450k | 100% | Dec 2025 |
|
| Manufacturers Life Insurance Company | 36k | $319k | -34% | Mar 2026 |
|
| Acadian Asset Management | 29k | $260k | 100% | Mar 2026 |
|
| XTX Topco | 29k | $359k | 22% | Dec 2025 |
|
| Vanguard Global Advisers | 18k | $163k | 100% | Mar 2026 |
|
| Axq Capital | 17k | $155k | 100% | Mar 2026 |
|
| Diametric Capital | 16k | $146k | 100% | Mar 2026 |
|
| Brevan Howard Capital Management | 14k | $128k | 100% | Mar 2026 |
|
| Quadrature Capital | 13k | $162k | 100% | Dec 2025 |
|
| Aquatic Capital Management | 12k | $106k | 100% | Mar 2026 |
|
| Atlantic Trust | 5.0k | $63k | 100% | Dec 2025 |
|
| Rockefeller Capital Management | 700.00 | $6.3k | 0% | Mar 2026 |
|
| Wells Fargo & Company | 300.00 | $2.7k | 0% | Mar 2026 |
|
| Barclays | 212.00 | $1.9k | 100% | Mar 2026 |
|
| Royal Bank of Canada | 154.00 | $999.999000 | 862% | Mar 2026 |
|
| Caitong International Asset Management | 4.00 | $36.000000 | 100% | Mar 2026 |
|
Who sold out of Bridgebio Oncology Therapeut?
| Fund or Company Name | Date Sold | Shares Held | Valued At |
|---|---|---|---|
| Silverarc Capital Management | Sep 2025 | 457k | $5.3M |
| Catalio Capital Management | Dec 2025 | 411k | $31M |
| ADAR1 Capital Management | Dec 2025 | 226k | $2.8M |
| Stempoint Capital | Dec 2025 | 87k | $1.1M |
| Point72 Asset Management | Dec 2025 | 24k | $295k |
| Persistent Asset Partners | Dec 2025 | 8.6k | $108k |